Generex Biotechnology Company (NASDAQ: GNBT), a drugdelivery system and technology developer, has filed an offering by sellingstockholders of up to 74,475,861 shares of common stock. The proposed maximum aggregateoffering price is …
Generex Biotechnology Corporation (GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company’s common stock will begin trading on a …
MIRAMAR, Fla.--(BUSINESSWIRE)-- Generex Biotechnology Corporation (OTCQB:GNBT - News) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today confirmed its receipt of the $700,000 USD …
Generex Biotechnology (GNBT) just announced a few minutes ago that results from ... Generex Biotechnology has since broken out of its narrow trading range and is now up 0.11 at $0.43. The stock is attempting to rebound from the lows of …
GNBT) have lost a whopping 74% so far this year, sending shares to a 52-week low of under 4 cents. The company shed nearly 10% in one day late last month after announcing a secondary stock offering. For more big news in the sector, …
Generex Biotechnology Corporation (GNBT) today announced that it has achieved the elimination ... Shares outstanding and convertible into 33,939,394 shares of Generex common stock (based on the VWAP as at that date). There were …
Often overlooked, adjuvants from GlaxoSmithKline and others can be an essential part of an effective cancer vaccine and could help advance the field even further.
Jan. 24, 2017 /PRNewswire/ -- Emmaus announced today that it has entered into a letter of intent (the "LOI") to …
Generex Biotechnology Corporation (GNBT) is pleased to announce that on January 16, 2017 it entered into a letter of intent (the “LOI”) for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc. …
(Comment on this article at http://www.financialwire.net/2010/04/21/insurance-in-focus-generex-establishes-reimbursement-plan-for-oral-lyn/) April 21, 2010 (FinancialWire) -- Generex Biotechnology Corp. (NASDAQ: GNBT) …